Danone Specialized Nutrition introduces SouvenaidTM, a medical food for the dietary management of early stages of Alzheimer’s disease


Danone Specialized Nutrition (Thailand) launches SouvenaidTM, a medical food that supports memory function in the early stages of Alzheimer’s disease (AD). This over-the-counter innovative product, for use under medical supervision, is backed by 20 years’ research into the nutritional needs of people living with the early stages of the disease.

SouvenaidTM which contains Fortasyn Connect, a specific combination of Omega-3 fatty acids, Choline, Uridine, B-vitamins, and antioxidants (Vit C, Vit E, Selenium), is able to provide significant benefits of cognitive and functional performance in patients with early Alzheimer’s disease, including mild cognitive impairments (MCI).[1]

The loss of connections in the brain (synapses) is one of the key features of early Alzheimer’s disease. A combination of nutrients is required for making new connections and people living with Alzheimer’s disease have been shown to have relatively low levels of these nutrients in their bodies (brain and plasma).2-3

“Research has shown that people with memory deteriorationin early Alzheimer’s disease often have low levels of key nutrients, despite eating a normal diet. SouvenaidTM has been designed to provide these essential nutrients at levels otherwise difficult to achieve through diet alone. The nutritional intervention by the use of SouvenaidTM is a new area of research offering promising results for the dietary management of early Alzheimer’s disease” said Danish Rahman, General Manager, Danone Thailand.

In Thailand, the reported prevalence of MCI in older people ranged from 15% to 70%, and it increased with age. Mild cognitive impairment (MCI) is considered as the earliest stage of Alzheimer’s. MCI patients will often show only mild symptoms and people will still be able to perform daily activities. The conversion of patients with MCI occurs at an annualized rate of 10 to 15% and 80% of these patients have converted to AD dementiaafter approximately 6 years of follow-up.4